Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDActual EPS
Theravance Biopharma, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | $0.10 | $0.10 | $0.10 |
| Q2 2025 | 1 | -$0.25 | -$0.25 | -$0.25 |
| Q3 2025 | 1 | -$0.21 | -$0.21 | -$0.21 |
| Q4 2025 | 1 | $0.18 | $0.18 | $0.18 |
| Q1 2026 | 0 | $0.00 | $0.00 | $0.00 |
| Q2 2026 | 0 | $0.00 | $0.00 | $0.00 |
| Q3 2026 | 0 | $0.00 | $0.00 | $0.00 |
| Q4 2026 | 0 | $0.00 | $0.00 | $0.00 |
Theravance Biopharma, Inc. Earnings Date And Information
Theravance Biopharma, Inc. last posted its earnings results on Wednesday, February 26th, 2025. The company reported $-0.05 earnings per share for the quarter, missing analysts' consensus estimates of $-0.05 by $0. The company had revenue of 18.75 M for the quarter and had revenue of 64.38 M for the year. Theravance Biopharma, Inc. has generated $-1 earnings per share over the last year ($-1.15 diluted earnings per share) and currently has a price-to-earnings ratio of -7.29. Theravance Biopharma, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 12th, 2025 based on prior year's report dates.
Theravance Biopharma, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 03/07/2025 | Q4 2024 | N/A | -$0.32 | N/A | $17.03 M | $18.75 M |
| 11/14/2024 | Q3 2024 | N/A | -$0.26 | N/A | $15.68 M | $16.87 M |
| 08/08/2024 | Q2 2024 | N/A | -$0.34 | N/A | $15.38 M | $14.26 M |
| 05/15/2024 | Q1 2024 | N/A | -$0.24 | N/A | $13.96 M | $14.50 M |
| 03/01/2024 | Q4 2023 | N/A | -$0.17 | N/A | $17.57 M | $17.57 M |
| 11/09/2023 | Q3 2023 | N/A | -$0.17 | N/A | $15.40 M | $15.69 M |
| 08/09/2023 | Q2 2023 | N/A | -$0.28 | N/A | $15.29 M | $13.75 M |
| 05/10/2023 | Q1 2023 | N/A | -$0.35 | N/A | $13.70 M | $10.42 M |
| 03/01/2023 | Q4 2022 | N/A | -$0.21 | N/A | $15.40 M | $14.65 M |
| 11/09/2022 | Q3 2022 | N/A | $12.14 | N/A | $11.81 M | $12.45 M |
| 08/08/2022 | Q2 2022 | N/A | -$0.11 | N/A | $12.50 M | $11.05 M |
| 05/06/2022 | Q1 2022 | N/A | -$0.34 | N/A | $14.40 M | $13.20 M |
| 02/28/2022 | Q4 2021 | N/A | -$0.44 | N/A | $13.49 M | $14.95 M |
| 11/08/2021 | Q3 2021 | N/A | -$0.48 | N/A | $14.40 M | $13.19 M |
| 08/05/2021 | Q2 2021 | N/A | -$0.80 | N/A | $15.41 M | $12.91 M |
| 05/06/2021 | Q1 2021 | N/A | -$1.24 | N/A | $17.27 M | $14.26 M |
| 02/26/2021 | Q4 2020 | N/A | -$0.92 | N/A | $19.87 M | $18.73 M |
| 11/09/2020 | Q3 2020 | N/A | -$1.16 | N/A | $18.58 M | $18.26 M |
| 08/10/2020 | Q2 2020 | N/A | -$1.00 | N/A | $19.64 M | $15.01 M |
| 05/08/2020 | Q1 2020 | N/A | -$1.40 | N/A | $18.13 M | $19.86 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Theravance Biopharma, Inc. Earnings: FAQ's
Theravance Biopharma, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 12th, 2025 based offlast year's report dates.
The conference call for Theravance Biopharma, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Theravance Biopharma, Inc.'s latest earnings report can be read online.
Theravance Biopharma, Inc. (:TBPH) has a recorded annual revenue of $64.38 M.
Theravance Biopharma, Inc. (:TBPH) has a recorded net income of $-56,418,000.Theravance Biopharma, Inc. has generated $-1.15 earnings per share over the last four quarters.
Theravance Biopharma, Inc. (:TBPH) has a price-to-earnings ratio of -7.29 and price/earnings-to-growth ratio is 0.49.